Press Releases

Announcements in the Media

You are here: Home / News / Press Releases

Apr 13


Kirk D. Malloy, Ph.D., Joins Edico Genome’s Board of Directors

SAN DIEGO, April 13, 2016 – Edico Genome today announced that Kirk D. Malloy, Ph.D., most recently the senior vice president and general manager of life sciences and applied markets at Illumina, Inc., has been appointed to the company’s board of directors. Dr. Malloy brings over twenty years of experience in life science executive leadership and management to Edico Genome’s board of directors, which includes Gregory T. Lucier, former chairman and chief executive officer of Life Technologies, Kenneth F. Buechler, Ph.D., co-founder and former president and chief scientific officer of Biosite Incorporated, Mark Bowles, co-founder of SalveoDx and Eco-ATM and Pieter van Rooyen, Ph.D., co-founder, president and chief executive officer of Edico Genome.

“Edico’s DRAGEN bioinformatics platform, a technology that is drastically reducing the time required to perform next-generation sequencing analysis, is clearly shaping the future of genomics,” said Dr. Malloy.  “I look forward to guiding the progress of a company that is revolutionizing precision medicine by eliminating the genomic data analysis bottleneck.”

Added Dr. van Rooyen of Edico Genome, “Kirk brings a wealth of commercial and scientific leadership capabilities that I am confident will help Edico continue the outstanding growth it experienced in 2015.”

As a long-term member of Illumina’s executive team, Dr. Malloy oversaw the company’s core platform technologies and was responsible for the over $1 billion life sciences and applied markets business unit, which includes agrigenomics, microbiology, healthy genomes and complex diseases. Dr. Malloy also currently serves on the board of directors for Organovo (ONVO). Dr. Malloy previously served as vice president of customer solutions and vice president of quality for Illumina, building and leading the company’s commercial support and training organization and a service business that generated more than $120 million in annual revenue. Prior to this, Dr. Malloy held commercial management positions at Biosite Incorporated and QIAGEN, Inc. He completed his doctorate in marine biochemistry at the University of Delaware and held postdoctoral and instructor positions at Boston University and Northeastern University.

About Edico Genome
Edico Genome has created the world’s first bioinformatics processor designed to analyze next-generation sequencing data, DRAGEN™. The use of next-generation sequencing is growing at an unprecedented pace, creating a need for a technology that can process this big data rapidly and accurately. Edico Genome’s computing platform has been shown to speed whole genome data analysis from hours to minutes, while maintaining high accuracy and reducing costs, enabling clinicians and researchers to reveal answers more quickly. For more information, visit or follow @EdicoGenome.